

CITATION REPORT

List of articles citing

Pharmacogenetic phenotyping and genotyping.
Present status and future potential

DOI: 10.2165/00003088-199426010-00005
Clinical Pharmacokinetics, 1994, 26, 59-70.

Source: <https://exaly.com/paper-pdf/25418497/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
149	The role of cytochrome P450 in developmental pharmacology. 1994 , 15, 635-40		19
148	A research agenda for the study of therapeutic agents in adolescents. 1994 , 15, 672-8		10
147	Assessment of liver metabolic function. Clinical implications. <i>Clinical Pharmacokinetics</i> , 1994 , 27, 216-48	6.2	104
146	Changes in the metabolism of three model substrates catalysed by different P450 isozymes when administered as a cocktail to the carbon tetrachloride-intoxicated rat. 1995 , 25, 1111-8		7
145	Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4Phydroxylation status. 1995 , 58, 143-54		127
144	Dipyron metabolism in liver disease. 1995 , 58, 198-209		17
143	Possible inhibition of hepatic metabolism of quinidine by erythromycin. 1995 , 57, 89-94		36
142	Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4Phydroxylation. 1995 , 58, 155-64		68
141	Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. 1995 , 103, 25-9		45
140	Molecular basis of polymorphic drug metabolism. 1995 , 73, 539-53		71
139	A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. 1995 , 96, 601-3		27
138	The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. 1995 , 23, 199-208		63
137	An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. <i>British Journal of Clinical Pharmacology</i> , 1995 , 40, 369-78	3.8	44
136	N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. <i>British Journal of Clinical Pharmacology</i> , 1995 , 40, 531-8	3.8	88
135	Clinical pharmacokinetics of dipyron and its metabolites. <i>Clinical Pharmacokinetics</i> , 1995 , 28, 216-34	6.2	148
134	An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. 1996 , 97, 668-70		23
133	Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. 1996 , 15, 273-80		247

132	Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. <i>Clinical Pharmacokinetics</i> , 1996 , 30, 263-99	6.2	209
131	Obtaining information about susceptibility from the epidemiological literature. 1996 , 111, 253-70		11
130	Developmental pharmacology: past, present and future. 1996 , 38, 555-61		5
129	Prediction of CYP2D6-mediated polymorphic drug metabolism (sparteine type) based on in vitro investigations. 1996 , 678, 93-103		4
128	Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. 1996 , 678, 113-28		58
127	The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. 1996 , 60, 522-34		143
126	Hepatic drug clearance in patients with mild cystic fibrosis. 1996 , 59, 529-40		16
125	Genotyping of S-mephenytoin 4Phydroxylation in an extended Japanese population. 1996 , 60, 661-6		241
124	Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. 1996 , 353, 207-12		46
123	Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole?. 1996 , 30, 364-6		32
122	Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance. <i>Critical Reviews in Toxicology</i> , 1997 , 27, 199-222	5-7	45
121	Ecogenetics: from ecology to health. 1997 , 13, 163-92		9
120	Drug metabolism: from experiments to regulatory aspects. <i>Drug Metabolism Reviews</i> , 1997 , 29, 853-86	7	3
119	Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. 1997 , 37, 834-40		10
118	Application of human liver microsomes in metabolism-based drug-drug interactions: in vitro-in vivo correlations and the Abbott Laboratories experience. 1997 , 43, 65-101		23
117	Overview of experimental approaches for study of drug metabolism and drug-drug interactions. 1997 , 43, 255-77		6
116	Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). 1997 , 75, 69-75		245
115	Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. <i>Clinical Pharmacokinetics</i> , 1997 , 32, 324-43	6.2	54

114	Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. <i>Clinical Pharmacokinetics</i> , 1997 , 33, 454-71	6.2	129
113	Pharmacogenetics in pediatrics. Implications for practice. 1997 , 44, 55-77		147
112	Genetic predisposition to drug-induced hepatotoxicity. 1997 , 26 Suppl 2, 12-21		81
111	Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. 1997 , 43, 254-266		144
110	The molecular biology of oral carcinogenesis: Toward a tumor progression model. 1997 , 55, 623-625		1
109	Oxidation of bilirubin by brain mitochondrial membranes--dependence on cell type and postnatal age. 1997 , 60, 155-60		32
108	Oxidation of bilirubin by rat brain mitochondrial membranes-genetic variability. 1997 , 62, 128-31		14
107	Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4Phydroxylation phenotype and genotype. 1997 , 62, 619-28		78
106	Cytochrome P450, molecular biology and anaesthesia. 1998 , 42, 1025-7		6
105	Exploring the hidden danger of noncardiac drugs. 1998 , 9, 1114-6		36
104	In vivo age-related changes in hepatic drug-oxidizing capacity in humans. 1998 , 23, 247-55		128
103	A validated method for the determination of paracetamol and its glucuronide and sulphate metabolites in the urine of HIV+/AIDS patients using wavelength-switching UV detection. 1998 , 17, 1191-7		22
102	Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. 1998 , 410, 245-70		106
101	Pharmacogenetics and cancer chemotherapy. 1998 , 34, 1493-9		78
100	Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. 1998 , 102-103, 143-7		45
99	Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. 1998 , 160, 102-4		11
98	Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. 1998 , 154, 47-85		176
97	Evaluation of the potential interaction between felbamate and erythromycin in patients with epilepsy. 1998 , 38, 184-90		11

96	Optimizing drug therapy based on genetic differences: implications for the clinical setting. 1998 , 9, 499-512; quiz 618-20		4
95	Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease. 1998 , 23, 161-70		25
94	Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. 1999 , 36 (Pt 6), 722-9		95
93	Implication of arylamine N-acetyltransferase (NAT2) polymorphism on levels of tumour markers CEA, AFP, CA 125, CA 19.9, and CA 15.3. 1999 , 4, 129-34		
92	Gender-related differences in pharmacokinetics and their clinical significance. 1999 , 24, 339-46		201
91	Mutations in the exons and exon-intron junction regions of human cytochrome P-4502E1 gene and alcoholism. 1999 , 23, 13S-16S		22
90	Polymorphic cytochromes P450 and drugs used in psychiatry. 1999 , 19, 325-54		35
89	Warfarin-acetaminophen drug interaction revisited. 1999 , 19, 1153-8		20
88	Quantitation of cytochrome P450 mRNAs in patients with suspected liver diseases as assessed by reverse transcriptase-polymerase chain reaction. 1999 , 134, 133-40		8
87	Characterization of Phase I and Phase II hepatic drug metabolism activities in a panel of human liver preparations. 1999 , 118, 151-69		48
86	Clinical Pharmacokinetics of Artemether and Lumefantrine (Riamet®). 1999 , 18, 467-480		59
85	Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. <i>Drug Metabolism Reviews</i> , 1999 , 31, 467-87	7	83
84	Biomarkers and molecular epidemiology and chemoprevention of oral carcinogenesis. 2000 , 11, 92-122		36
83	Pharmacogenomics of cytochrome P450 and other enzymes involved in biotransformation of xenobiotics. 2000 , 49, 4-16		28
82	Pharmacogenetics and psychopharmacotherapy. 2000 , 25, 197-220		168
81	Development and characterization of a rapid and comprehensive genotyping assay to detect the most common variants in cytochrome P450 2D6. 2000 , 17, 242-6		7
80	Pharmacogenomics: the promise of personalized medicine. 2000 , 2, E4		133
79	Human variability and susceptibility to trichloroethylene. 2000 , 108 Suppl 2, 201-14		26

78	Pharmakogenetische Aspekte der Arzneimitteltherapie. Pharmacogenetics in Drug Therapy. 2000 , 24, 182-189		1
77	Acetaminophen intoxication during treatment: what you don't know can hurt you. 2000 , 39, 133-44		21
76	Pharmacogenetic screening for susceptibility to fetal malformations in women. 2000 , 34, 639-45		14
75	Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. 2000 , 30, 1131-52		295
74	Drug-induced liver diseases. 2000 , 32, 77-88		146
73	The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. 2001 , 120, 199-208		63
72	[Pharmacogenetics of cytochromes P450: practical implications]. 2001 , 8 Suppl 2, 350s-352s		
71	Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer. 2001 , 274, 93-102		23
70	Terbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjects. <i>British Journal of Clinical Pharmacology</i> , 2001 , 51, 107-8	3.8	4
69	Drug metabolism and drug interactions in the elderly. 2001 , 15, 897-918		80
68	Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2001 , 51, 164-8	3.8	1
67	Understanding the role of xenobiotic-metabolism in chemical carcinogenesis using gene knockout mice. 2001 , 477, 79-87		40
66	Population pharmacokinetics of intramuscular quinine in children with severe malaria. 2001 , 45, 1803-9		40
65	Important role of prodromal viral infections responsible for inhibition of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye's syndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and hepatotoxicity of the therapeutic doses of acetaminophen used in genetically predisposed persons. 2002 , 9, 149-56		20
64	Genotyping and phenotyping the cytochrome p-450 enzymes. 2002 , 9, 309-16		19
63	Childhood asthma: new insights into management. 2002 , 109, 3-13		29
62	Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation. 2002 , 21, 123-41		48
61	Genotyping analysis as a possible predictor of pharmacokinetic and clinical effects of antipsychotic drugs. 2002 , 1244, 111-118		

60	Correlation of tramadol pharmacokinetics and CYP2D6*10 genotype in Malaysian subjects. 2002 , 30, 189-195		36
59	Transgenic models in xenobiotic metabolism and toxicology. 2002 , 181-182, 237-9		19
58	Increased transcriptional activity of the CYP3A4*1B promoter variant. 2003 , 42, 299-305		146
57	CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. 2003 , 22, 476-85		131
56	Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug. <i>British Journal of Clinical Pharmacology</i> , 2003 , 55, 191-8	3.8	10
55	A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. <i>British Journal of Clinical Pharmacology</i> , 2003 , 56, 220-4	3.8	31
54	Study of P450 function using gene knockout and transgenic mice. 2003 , 409, 153-8		94
53	Alteration of glutathione S-transferase levels in Barrett's metaplasia compared to normal oesophageal epithelium. 2003 , 15, 41-7		11
52	THE FATE OF XENOBIOTICS IN LIVING ORGANISMS. 2003 , 501-515		1
51	Effect of a 4-month tea intervention on oxidative DNA damage among heavy smokers: role of glutathione S-transferase genotypes. 2004 , 13, 242-9		38
50	Principles of pharmacogenetics--implications for the anaesthetist. 2004 , 93, 440-50		28
49	Relationship between Type A and B personality and debrisoquine hydroxylation capacity. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 785-9	3.8	34
48	Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. <i>Drug Metabolism Reviews</i> , 2004 , 36, 243-77	7	102
47	Physicochemical and biological data for the development of predictive organophosphorus pesticide QSARs and PBPK/PD models for human risk assessment. <i>Critical Reviews in Toxicology</i> , 2004 , 34, 143-207	5.7	51
46	Human papillomavirus and disease mechanisms: relevance to oral and cervical cancers. <i>Oral Diseases</i> , 2005 , 11, 350-9	3.5	83
45	Pharmacogenetics of Antidepressant Drug Metabolism and Its Clinical Implications. 2005 , 879-902		
44	Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 977-88	6.2	34
43	Detoxification and biotransformational imbalances. <i>Explore: the Journal of Science and Healing</i> , 2006 , 2, 122-40	1.4	18

42	Effect of the immunomodulant ximedone on the pharmacokinetics of isonicotinic acid hydrazide in the human organism. <i>Pharmaceutical Chemistry Journal</i> , 2006 , 40, 119-123	0.9	
41	Antidepressant-drug interactions are potentially but rarely clinically significant. <i>Neuropsychopharmacology</i> , 2006 , 31, 1594-604; discussion 1614-5	8.7	27
40	Expression, purification, and characterization of mouse CYP2d22. <i>Drug Metabolism and Disposition</i> , 2006 , 34, 1167-74	4	23
39	Ethnicity and psychopharmacology. <i>Journal of Psychopharmacology</i> , 2008 , 22, 673-80	4.6	54
38	Green tea consumption is associated with decreased DNA damage among GSTM1-positive smokers regardless of their hOGG1 genotype. <i>Journal of Nutrition</i> , 2008 , 138, 1567S-1571S	4.1	39
37	Pharmacogenetics of ethnic populations. 62-86		
36	Relationship between Genetic Polymorphism of CYP1A1 at Codon 462 (Ile462Val) in Colorectal Cancer. <i>International Journal of Biological Markers</i> , 2008 , 23, 18-23	2.8	1
35	Pharmacogenetics and blood dyscrasias. <i>European Journal of Haematology</i> , 1996 , 60, 93-7	3.8	3
34	Autism spectrum disorders may be due to cerebral toxoplasmosis associated with chronic neuroinflammation causing persistent hypercytokinemia that resulted in an increased lipid peroxidation, oxidative stress, and depressed metabolism of endogenous and exogenous substances. <i>Research in Autism Spectrum Disorders</i> , 2010 , 4, 119-155	3	30
33	CYP1A1 Ile462Val polymorphism contributes to colorectal cancer risk: a meta-analysis. <i>World Journal of Gastroenterology</i> , 2011 , 17, 260-6	5.6	16
32	Infusion of pharmacogenetics into cancer care. <i>Seminars in Oncology Nursing</i> , 2011 , 27, 45-53	3.7	6
31	Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis. <i>Pediatric Blood and Cancer</i> , 2011 , 57, 578-82	3	21
30	Impact of obesity on drug metabolism and elimination in adults and children. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 277-304	6.2	226
29	Questions regarding the predictive value of one evolved complex adaptive system for a second: exemplified by the SOD1 mouse. <i>Progress in Biophysics and Molecular Biology</i> , 2013 , 113, 231-53	4.7	25
28	Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. <i>Molecular Psychiatry</i> , 2013 , 18, 273-87	15.1	111
27	ADHD pharmacogenetics across the life cycle: New findings and perspectives. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2014 , 165B, 263-82	3.5	34
26	Beta Receptor Antagonists. 2015 , 1-16		
25	Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. <i>Journal of Internal Medicine</i> , 2015 , 277, 167-177	10.8	42

24	Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. <i>Advances in Experimental Medicine and Biology</i> , 1999 , 455, 147-52	3.6	41
23	Xenobiotic Metabolism: From Intact Biosystem to Single Enzymes. 1994 , 1-19		1
22	Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 237-44	3.2	73
21	On the assessment of drug metabolism by assays of codeine and its main metabolites. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 258-65	3.2	10
20	Applications of Heterologous Expressed and Purified Human Drug-Metabolizing Enzymes. 1999 , 279-320		8
19	Pharmacogenetics. 1999 , 175-202		4
18	The Ethical Implications for Humans in Light of the Poor Predictive Value of Animal Models. <i>International Journal of Clinical Medicine</i> , 2014 , 05, 966-1005	0.3	2
17	Metabolism of Chemotherapeutic Drugs by Maternal and Conceptus Tissues. 2001 , 149-173		
16	Ecogenetics: The Study of Gene-Environment Interactions.		
15	References. 2001 , 164-210		
14	Pharmacogenetics.		
13	Polymorphism and Alcoholic Liver Disease The author thanks Dr Julio Mayol for helpful discussion and revision of the manuscript.. 2005 , 481-490		
12	Sudden Cardiac Death. 2007 , 2039-2083		
11	Antiprotozoal and Anthelmintic Agents. 2011 , 581-611		
10	Regulation of Xenobiotic-Metabolizing Cytochromes P450. 1994 , 21-42		
9	Drug Metabolism in the Neonate and Young Infant. <i>Update in Intensive Care and Emergency Medicine</i> , 1996 , 385-399		
8	Prädiktiver Wert von in vitro-Experimenten für den Arzneimittelstoffwechsel des Menschen: Vergleich mit anderen in vitro-Modellen. <i>Ersatz- Und Ergänzungsmethoden Zu Tierversuchen</i> , 1998 , 61-67		
7	Pharmacogenetics Polymorphisms in Xenobiotic Metabolism. 1999 , 91-110		1

- 6 Psicofarmacogenética: uma nova abordagem terapêutica. *Revista Brasileira De Psiquiatria*, **1999**, 21, 27-30 2.6
- 5 Beta-Receptor Antagonists. **2017**, 771-786
- 4 Beta Receptor Antagonists. **2018**, 1-16
- 3 Impact of Gene Variability on Drug Metabolism. **2005**, 269-294
- 2 Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?. *American Journal of Human Genetics*, **1997**, 60, 265-71 11 148
- 1 The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. *Microbial Pathogenesis*, **2021**, 162, 105311 3.8 0